@Article{Surkont2006,
journal="Menopause Review/Przegląd Menopauzalny",
issn="1643-8876",
volume="5",
number="1",
year="2006",
title="Solifenacin \– first experiences in overactive bladder treatment",
abstract="  Aim of the study:   In the article we presented first our experiences with ovaractive bladder (OAB) treatment with the use of new antimuscarinic drug Vesicare (Astellas).    Material and methods:   In the analysis we included first 20 patients aged 57-81 with OAB complaints. We analised first two months of treatment with solifenacin used in oral tablets in dose 5 mg given once daily. Patients were evaluted before and after 8 weeks of treatment. In the study we evaluated the efficacy of treatment and patient\’s compliance.    Conclusions:    Solifenacin in 5 mg dose is efficient in OAB treatment. It is well tolerated. Side effects on low level are rare. These conclusions are preliminary. More detailed analysis will be possible after long-time evaluations on bigger numbers of patients.",
author="Surkont, Grzegorz
and Wlaźlak, Edyta
and Suzin, Jacek",
pages="43--46",
url="https://www.termedia.pl/Solifenacin-8211-first-experiences-in-overactive-bladder-treatment,4,5549,1,1.html"
}